Citation

Simin S, Shahnaz S, Azadeh L, Mehdi K, Javad M. Novelty Biomed. 2017; 5(4): 172-176.

Copyright

(Copyright © 2017)

DOI

unavailable

PMID

unavailable

Abstract

BACKGROUND: Hepatitis C infection is a worldwide problem. In Iran, hepatitis C virus [HCV] infection prevalence is about 1-2%. A combination therapy of pegylated interferon alfa-2a and ribavirin [PEG-IFNalpha/RBV] is a standard treatment, but our aim was to determine the efficacy and safety of dual PEG-IFNalpha/RBV therapy in treating patients infected with HCV in Iranian context

Language: en